Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
US$410.77
+5.46+1.35%
After hoursUS$412.82+0.50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 316.69億 | 372.61億 | 419.58億 | 483.11億 | 536.73億 |
| Gross profit | 187.6億 | 215.28億 | 238.96億 | 264.59億 | 323.39億 |
| Operating income | 62.56億 | 76.2億 | 78.45億 | 95.81億 | 117.16億 |
| Net income | 48.83億 | 56.3億 | 61.71億 | 57.75億 | 76.46億 |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief